Biomarker of Diabetic Retinopathy
NCT05079399
Cardiovascular Diseases, Diabetes Complications
Carmel, Indiana, United States
View Trial DetailsNCT Number: NCT04240652
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Ruijin hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai Municipality, China
The greatest harm of diabetes is various acute and chronic complications, especially DR, leading to extremely high rates of disability and blindness. However, if the fundus examination is carried out regularly in the early stages of onset, the risk of blindness can be significantly reduced. Therefore, early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate.
The Diabetic Retinopathy Screening and Prevention Program is a branch project of MMC. Its purpose is to carry out an efficient workflow for early detecting, timely managing of DR, and to establish a referral system for implementing treatment and the long-term follow-up of DR by means of DL. First, In order to improve its sensitivity and specificity, more participants are involved in other medical institutes besides MMCs, then we can effectively explore the prevalance of DR in China and helps to early screening, prevention, treatment and referal process of DR. Secend, we collect participants' serum, plasma,DNA, several medical stastistics and life styles to explore genetics, new biomarkers, risk factors of DR.
Objective:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For detailed In-/Ex-clusion criteria please see the study protocol.
Time frame: through study completion, up to 20 years
diabetic retinopathy
Time frame: through study completion, up to 20 years
Referable diabetic retinopathy
Time frame: through study completion, up to 20 years
Vision threatening diabetic retinopathy
Time frame: through study completion, up to 20 years
Diabetic macular edema
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Body weight (kg) and height (m) will be combined to report BMI in kg/m^2
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Time frame: through study completion, up to 20 years
Contact information is provided by the study sponsor or research team.
Shanghai Jiao Tong University School of Medicine
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05079399
Cardiovascular Diseases, Diabetes Complications
Carmel, Indiana, United States
View Trial DetailsNCT07592273
Cardiovascular Diseases, Diabetes Complications
Phoenix, Arizona, United States
View Trial DetailsNCT07588100
Cardiovascular Diseases, Diabetes Complications
Glendale, California, United States
View Trial DetailsNCT06701721
Cardiovascular Diseases, Diabetes Complications
Parramatta, New South Wales, Australia
View Trial Details